Privacy-preserving AI platform that reduces patient recruitment time in pharmaceutical trials by 30% using federated learning and EHR analysis without moving sensitive data.
BioMatch addresses the $2B+ annual problem of patient recruitment delays in clinical trials through groundbreaking privacy-preserving technology. Our federated learning platform analyzes electronic health records across multiple healthcare providers without transferring sensitive data, cutting recruitment time by 30% while maintaining full HIPAA/GDPR compliance. This solution directly serves pharmaceutical companies and research organizations struggling with trial delays that cost millions per day.
Core Functionality
BioMatch utilizes federated learning technology to analyze de-identified electronic health records and genetic data across multiple healthcare providers without moving sensitive information. The platform features an advanced eligibility matching algorithm, privacy-preserving analytics dashboard, and automated patient consent management system. This allows researchers to identify potential trial participants while maintaining complete data security and regulatory compliance.
Target User and Segment
Our primary customers include pharmaceutical R&D departments, Contract Research Organizations (CROs), and large hospital networks conducting clinical trials in North American and EU markets. We initially focus on oncology, rare diseases, and chronic conditions where recruitment challenges are most severe and trial delays most costly.
Recommended Tech Stack
- Python/TensorFlow Federated for machine learning implementation
- React/Node.js frontend for responsive dashboard
- HIPAA/GDPR-compliant AWS infrastructure
- Blockchain technology for immutable audit trails
- FHIR API integrations for EHR connectivity
- Zero-knowledge proof protocols for enhanced privacy
Estimated MVP Hours and Costs
Based on €100/hour development rate:
- Backend development: 800 hours (€80,000)
- Federated learning implementation: 1,200 hours (€120,000)
- EHR integration modules: 1,000 hours (€100,000)
- Frontend dashboard: 600 hours (€60,000)
- Compliance and security: 800 hours (€80,000)
- Testing and validation: 400 hours (€40,000)
- Total MVP investment: €480,000 (4,800 hours)
SWOT Analysis
Strengths: First-mover in privacy-preserving trial matching, addresses massive recruitment delay costs, strong IP potential in proprietary algorithms
Weaknesses: Complex regulatory landscape, dependency on hospital EHR cooperation, high computational requirements
Opportunities: Growing $96B precision medicine market by 2028, FDA pushing digital transformation, COVID-accelerated telehealth adoption
Threats: Emerging competitors like Deep 6 AI, potential regulatory changes, hospital system consolidation
First 1000 Customers Strategy
Acquisition channels include direct enterprise sales to top pharmaceutical companies (€15k CAC), medical conference sponsorship (€25k budget), partnerships with CROs through revenue share models, and referral programs for research hospitals. We project a 3% enterprise conversion rate with 12-month sales cycle, targeting 10 pilot hospitals in Year 1 with €300,000 allocated for initial sales and marketing efforts.
Monetization
Business Model: SaaS subscription with tiered pricing: Basic (€50k/trial), Enterprise (€200k/trial + success fees), Platform license (€1M/annual).
Pricing Assumptions: Average contract value €150k, targeting 15 trials in Year 1, growing to 100+ by Year 3.
Break-even Analysis: Requires 4 enterprise contracts to cover annual operations (€2.1M burn rate), projected Month 18 breakeven.
Core Personnel: CTO (€120k), 3 ML engineers (€90k each), Head of Regulatory (€110k), 2 Enterprise sales (€80k + commission), CEO (€130k).
Market Positioning and Competitors
We target the North American clinical trial market ($45B) and EU market ($38B) with 20% annual growth in digital solutions. Key competitors include Deep 6 AI ($55M raised) and TriNetX, but our privacy-by-design approach differentiates by avoiding data centralization. Sales strategy focuses on land-and-expand with pharma enterprises, leveraging regulatory consultants as channels, and targeting high-value orphan drug trials first. Market niches include rare disease trials (85% recruitment delays) and EU markets with strict GDPR requirements.
